Targeting agents alone to cure acute promyelocytic leukemia

New England Journal of Medicine

Volumn 369, Issue 2, 2013, Pages 186-187

  Chen, Sai Juan ^a   Chen, Zhu ^a  

^a not available ^*

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; RETINOIC ACID;

CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; DISEASE FREE SURVIVAL; EDITORIAL; EVENT FREE SURVIVAL; GENE PRODUCT; HUMAN; PRIORITY JOURNAL; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; PROTEIN TARGETING; QT INTERVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE;

EID: 84880268797     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1304762     Document Type: Editorial

References (10)

1. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15.
2. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009;114:5126-35.
3. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2009;106:3342-7.
4. Zhang XW, Yan XJ, Yang FF, et al. Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science 2010;328:240-3. [Erratum, Science 2010;328:974.]
5. de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010;10:775-83.
6. Chen SJ, Zhou GB, Zhang XW, et al. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011;117:6425-37.
7. Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med 2008;14:1333-42. [Erratum, Nat Med 2009;15:117.]
8. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013;369:111-21.
9. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-53. (Pubitemid 30658450)
10. Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011;118:5593-603.